MRNS - Marinus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.46
-0.09 (-1.98%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.55
Open4.54
Bid3.81 x 3000
Ask5.35 x 800
Day's Range4.22 - 4.61
52 Week Range3.31 - 10.54
Volume489,111
Avg. Volume725,624
Market Cap180.742M
Beta (3Y Monthly)5.28
PE Ratio (TTM)N/A
EPS (TTM)-0.87
Earnings DateJul 30, 2018 - Aug 3, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.50
Trade prices are not sourced from all markets
  • Granite Point Capital’s Returns, AUM, and Holdings
    Insider Monkeyyesterday

    Granite Point Capital’s Returns, AUM, and Holdings

    Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]

  • Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?
    Zacks11 days ago

    Is the Options Market Predicting a Spike in Marinus Pharmaceuticals (MRNS) Stock?

    Investors need to pay close attention to Marinus Pharmaceuticals (MRNS) stock based on the movements in the options market lately.

  • GlobeNewswire11 days ago

    Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 06, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Associated Press19 days ago

    Marinus Pharmaceuticals: 3Q Earnings Snapshot

    The Radnor, Pennsylvania-based company said it had a loss of 27 cents per share. Marinus Pharmaceuticals shares have dropped 38 percent since the beginning of the year. The stock has dropped 16 percent ...

  • GlobeNewswire19 days ago

    Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results

    RADNOR, Pa., Oct. 29, 2018 -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative.

  • GlobeNewswirelast month

    Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance

    Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the appointment of Rolando Gutíerrez-Esteinou, M.D., as Vice President of Clinical Development and Pharmacovigilance where he will primarily be responsible for the medical leadership of our postpartum depression (PPD) programs and drug safety. “Dr. Gutíerrez-Esteinou is a welcome addition to the management team at Marinus,” said Christopher Cashman, Chairman and CEO of Marinus Pharmaceuticals.

  • GlobeNewswirelast month

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 120,000 shares of its common stock to a new employee, with a grant date of October 8, 2018. The options will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's start date, and will vest and become exercisable as to the remaining 75 percent of the shares in 36 equal monthly installments at the end of each month following the anniversary, subject to the employee's continued employment with Marinus on such vesting dates.  The stock options were granted as inducements material to the new employee entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant.

  • GlobeNewswirelast month

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 20,000 shares of its common stock each to two new employees, with grant dates of October 1 and October 3, 2018. The stock options were granted as inducements material to the new employees entering into employment with Marinus in accordance with NASDAQ Listing Rule 5635(c)(4), and are subject to the terms and conditions of a stock option agreement covering the grant. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • Simply Wall St.2 months ago

    What Kind Of Shareholders Own Marinus Pharmaceuticals Inc (NASDAQ:MRNS)?

    A look at the shareholders of Marinus Pharmaceuticals Inc (NASDAQ:MRNS) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge Read More...

  • GlobeNewswire2 months ago

    Marinus Completes Enrollment in its Magnolia Postpartum Depression Study

    Marinus Pharmaceuticals, Inc. (MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has recently completed enrollment in its Magnolia Study – a Phase 2 clinical trial evaluating the safety, pharmacokinetics and efficacy of ganaxolone in women with postpartum depression. “The completion of enrollment in our Magnolia Study is an important milestone in studying PPD, for which there is currently no approved treatment,” said Christopher Cashman, chairman and CEO of Marinus Pharmaceuticals.

  • ACCESSWIRE2 months ago

    Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market

    HENDERSON, NV / ACCESSWIRE / September 20, 2018 / Small biotech companies have been receiving a ton of interest this year. Just last week, Boehringer Ingelheim's shopping spree continued with a €210m takeover of ViraTherapeutics, an oncolytic virus specialist it has been working with since 2016. Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, has recently announced an amendment to its Registration trial in ocular melanoma liver metastases, a disease that has shown resistance to the new immunotherapies.

  • GlobeNewswire2 months ago

    Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that the Compensation Committee of the Board of Directors of Marinus granted non-qualified stock options to purchase an aggregate of 42,000 shares of its common stock to a new director and a new employee, with a grant date of September 19, 2018. Ganaxolone is a positive allosteric modulator of GABAA that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects.

  • GlobeNewswire3 months ago

    Marinus Pharmaceuticals to Present at the Baird Healthcare Conference

    Marinus Pharmaceuticals, Inc. (MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Christopher M. Cashman, Chief Executive Officer will present a company overview at the Baird 2018 Healthcare Conference on Thursday, September 6, 2018 at 2:00 p.m. ET.  The conference will take place in New York. Marinus Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of ganaxolone, which offers a new mechanism of action, demonstrated efficacy and safety, and convenient dosing to improve the lives of patients suffering from epilepsy and neuropsychiatric disorders.

  • GlobeNewswire3 months ago

    Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind ...

  • 7 Biotech Stocks With Big Upcoming Catalysts
    Kiplinger3 months ago

    7 Biotech Stocks With Big Upcoming Catalysts

    Are you ready? Biotech stocks provide a compelling opportunity for risk-tolerant investors looking for rich rewards. Regardless of market sentiment, economic data or trade wars, a key regulatory approval or trial data can send prices rocketing. Consider Madrigal Pharma (MDGL), which exploded by nearly 150% back in May following positive Phase 2 results for a liver-disease treatment. Of course, the opposite can also be true - prices can fall just as quickly if data or approvals fail to impress. That's why it's so crucial to conduct thorough research before investing in this high-potential (but high-risk) area of the market. For instance, using TipRanks, we can assess both the analyst consensus rating (all the stocks covered below are a "Moderate Buy" or "Strong Buy") and the expected upside potential based on recent ratings. Here are seven biotech stocks that could be catapulted higher by near-term catalysts. We'll also explore the pros' analysis and price targets for each company. SEE ALSO: The 18 Best Stocks to Buy for the Rest of 2018

  • Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today
    Motley Fool4 months ago

    Here's Why Marinus Pharmaceuticals Inc. Fell as Much as 20.1% Today

    The small biopharma announced second-quarter 2018 results and gave a business update.

  • Associated Press4 months ago

    Marinus Pharmaceuticals: 2Q Earnings Snapshot

    On a per-share basis, the Radnor, Pennsylvania-based company said it had a loss of 24 cents. Marinus Pharmaceuticals shares have declined 14 percent since the beginning of the year. The stock has nearly ...

  • Benzinga4 months ago

    Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus

    The biotech space represents a gold mine of opportunity for investors to multiply their investment returns, courtesy of the volatility generated by market-moving catalysts. In a note this week, Canaccord ...

  • ACCESSWIRE4 months ago

    Free Technical Research on Marinus Pharma and Three More Biotech Equities

    LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on MRNS sign up now at www.wallstequities.com/registration. On Friday, July 13, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Friday's trading session in bullish territories.

  • TheStreet.com4 months ago

    Pfizer Doesn't Look Fundamentally or Technically Strong

    The best-looking trading group right now is the small oil stocks, but even those have thinned out after a few days of strong action. There are also a few biotech names making an effort to turn, but that's sparse, too. PFE also said that it's going to suspend drug-price increase that went into effect July 1 and will keep them on hold there until President Donald Trump unveils his plan to strengthen the U.S. health-care system.